Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 4NET 1

Conditions

Neuroendocrine Tumors 3Neoplasms 2Vipoma 1Somatostatinoma 1Pheochromocytoma 1Nephroma, Mesoblastic 1Myeloproliferative Disorders 1Melanoma 1Lymphoproliferative Disorders 1Insulinoma 1Glucagonoma 1Gastro-entero Pancreatic Neuroendocrine Tumors 1Gastrinoma 1Ganglioneuroma 1Desmoid Tumors 1Central Nervous System Neoplasms 1Carcinoma, Islet Cell 1Carcinoma in Situ 1Adenoma, Islet Cell 1

Interventions

motesanib diphosphate 1batifiban 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Carcinoma, Islet Cell × NET × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡